DCE Platform®—More Efficient and Less Expensive
Unlike traditional methods of drug discovery which involve lengthy processes with high failure rates, our approach generally begins with approved drugs. We prioritize candidate compounds based on the medical needs of patients, commercial opportunity, regulatory considerations, competitive landscape and strategic business fit. Our approach aims to enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development.
Our DCE Platform consists of the proprietary know-how, techniques and information that the Concert team has developed for nearly a decade. Deuterated compounds can have an increased half-life in the body and increased systemic exposure as compared to their corresponding non-deuterated analogs, and these properties can lead to therapeutic benefits such as improved safety, efficacy, tolerability and convenience. As a result of Concert’s significant experience in deuterium chemistry and pharmaceutical research and development, the Company is well positioned to efficiently identify compounds that can benefit from deuterium modification and create optimally-designed deuterated product candidates.
We apply our DCE Platform to identify previously studied compounds, including approved drugs, that we believe can be improved with deuterium substitution. Potential advantages of our selective incorporation of deuterium in drug compounds include:
- Improved metabolic profile. We have selectively incorporated deuterium into compounds to improve their metabolic profiles by reducing the formation of toxic or reactive metabolites or by increasing the formation of desired, active metabolites relative to the corresponding non-deuterated compound. The improved metabolic profile of a deuterated compound may potentially improve efficacy or reduce or eliminate unwanted side effects or undesirable drug interactions.
- Improved oral bioavailability. We have selectively incorporated deuterium into orally administered compounds to reduce the extent of undesired metabolism in the wall of the intestines and in the liver, referred to as first-pass metabolism. This results in a larger percentage of unmetabolized drug reaching the target site of action. Deuterated compounds with improved bioavailability may be active at lower doses and may have improved tolerability.
- Increased half-life. We have selectively incorporated deuterium into compounds to prolong their pharamacokinetic profile, which is an increase in the half-life of the compound in the body. This may decrease the number of doses that a patient is required to take per day or provide more consistent exposure of the compound in comparison to a similar non-deuterated compound. In certain cases, improved consistency of exposure can lead to enhanced efficacy and/or tolerability.